Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

January 2025
Tes Pharma Renews Research and Development Collaboration with Intercept Pharmaceuticals
Tes Pharma, a biotech company focused on delivering first-in-class therapeutics for high unmet medical needs in oncology renal and metabolic diseases based in OpenZone, today announced the renewal of its research and development collaboration with Intercept Pharmaceuticals, Inc. (Intercept), a wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases.   
 
As part of the collaboration, which began in 2015, Intercept purchased from Tes Pharma the rights to INT-787, a selective next generation Farnesoid X Receptor (FXR) agonist that showed strong anti-fibrotic and anti-inflammatory effects in animal models and is currently in clinical development for the treatment of severe alcohol-associated hepatitis (sAH).
Professor Roberto Pellicciari 
Founder and Chief Scientific Advisor of Tes Pharma

We are very pleased on the renewal of the collaboration with Intercept. The success of this long-standing collaboration encourages us to continue our mission to find new treatments to help improve people’s lives, especially for patients suffering from serious diseases.

Act 

News
There is a lot of news to share about OpenZone. Make sure you're always up-to-date.
tutte le news